Stockreport

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer [Yahoo! Finance]

Imunon, Inc.  (IMNN) 
PDF Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women's health are encouraged to attend, either In-person or virtuall [Read more]